11:06 AM EST, 01/06/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.
The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.
ARS Pharmaceuticals ( SPRY ) also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.
Shares of the company declined more than 1% in recent trading activity.
Price: 10.99, Change: -0.21, Percent Change: -1.83